# A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

> **NCT06208826** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 268 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** Radiation Therapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06208826
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208826, "A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06208826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*